ProQR Therapeutics (PRQR) News Today → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free PRQR Stock Alerts $1.94 +0.02 (+1.04%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 5:52 AM | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Below 200 Day Moving Average of $1.97May 18 at 3:50 AM | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Upgraded by StockNews.com to HoldMay 14, 2024 | americanbankingnews.comChardan Capital Reiterates "Buy" Rating for ProQR Therapeutics (NASDAQ:PRQR)May 14, 2024 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Stock Rating Reaffirmed by HC WainwrightMay 13, 2024 | finance.yahoo.comShareholders in ProQR Therapeutics (NASDAQ:PRQR) are in the red if they invested five years agoMay 12, 2024 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.comMay 11, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Cut to "Sell" at StockNews.comStockNews.com downgraded shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.May 10, 2024 | markets.businessinsider.comProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development PotentialMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial FootingMay 10, 2024 | marketbeat.comProQR Therapeutics' (PRQR) "Buy" Rating Reaffirmed at Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $2.50 target price on shares of ProQR Therapeutics in a report on Friday.May 9, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comProQR Announces First Quarter 2024 Operating and Financial ResultsMay 8, 2024 | markets.businessinsider.comBuy Recommendation on ProQR’s Innovative RNA Editing Platform and Promising Clinical ProspectsMay 8, 2024 | stockhouse.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer(TM) RNA Editing Program Targeting NTCP for Cholestatic DiseasesMay 8, 2024 | finance.yahoo.comProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic DiseasesApril 24, 2024 | stockhouse.comProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual MeetingApril 23, 2024 | globenewswire.comProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024April 22, 2024 | finance.yahoo.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 22, 2024 | globenewswire.comProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingApril 21, 2024 | uk.investing.comProQR retains key patent for RNA editing technologyApril 20, 2024 | stockhouse.comProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP PortfolioApril 19, 2024 | globenewswire.comProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioApril 18, 2024 | marketbeat.comCitigroup Raises ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00Citigroup increased their target price on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the company a "buy" rating in a research report on Thursday.April 8, 2024 | finance.yahoo.comProQR Therapeutics N.V. (PRQR)March 29, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by AnalystsProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been assigned a consensus rating of "Buy" from the five analysts that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have coveredMarch 18, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.00 price objective on shares of ProQR Therapeutics in a report on Thursday.March 18, 2024 | marketbeat.comChardan Capital Boosts ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.50Chardan Capital lifted their price objective on shares of ProQR Therapeutics from $2.00 to $2.50 and gave the company a "buy" rating in a research note on Thursday.March 15, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Short Interest UpdateProQR Therapeutics (NASDAQ:PRQR - Get Free Report) saw a large drop in short interest in February. As of February 29th, there was short interest totalling 263,900 shares, a drop of 17.3% from the February 14th total of 319,000 shares. Based on an average trading volume of 302,700 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.6% of the shares of the stock are short sold.March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic DisordersMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing PlatformMarch 14, 2024 | finance.yahoo.comProQR Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | globenewswire.comProQR Announces Year End 2023 Operating and Financial ResultsMarch 11, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Upgraded by StockNews.com to BuyStockNews.com upgraded ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday.February 18, 2024 | finance.yahoo.comPRQR Mar 2024 2.500 callFebruary 16, 2024 | wsj.comProQR Therapeutics N.V.February 15, 2024 | finance.yahoo.comProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA EditingFebruary 8, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by BrokeragesProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been assigned an average recommendation of "Buy" from the five research firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average 12 month price target among analyFebruary 2, 2024 | marketbeat.comStockNews.com Downgrades ProQR Therapeutics (NASDAQ:PRQR) to HoldStockNews.com lowered shares of ProQR Therapeutics from a "buy" rating to a "hold" rating in a report on Friday.January 30, 2024 | stocknews.com4 Biotech Stocks With Massive Buy PotentialJanuary 25, 2024 | marketbeat.comStockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to BuyStockNews.com raised ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.January 19, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024January 19, 2024 | finance.yahoo.comProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024January 15, 2024 | finance.yahoo.comWhile institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the mostJanuary 13, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Sees Large Decrease in Short InterestProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 680,400 shares, a decrease of 30.6% from the December 15th total of 981,100 shares. Based on an average trading volume of 204,200 shares, the short-interest ratio is currently 3.3 days. Currently, 1.4% of the company's shares are sold short.January 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProQR on Strategic Partnership and Promising Axiomer RNA Editing PlatformJanuary 5, 2024 | finanznachrichten.deProQR Therapeutics N.V.: ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing CollaborationJanuary 5, 2024 | benzinga.comProQR Therapeutics Stock (NASDAQ:PRQR) Dividends: History, Yield and DatesJanuary 5, 2024 | finance.yahoo.comProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing CollaborationJanuary 4, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by StockNews.comStockNews.com raised ProQR Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday.December 28, 2023 | finance.yahoo.comIs ProQR (PRQR) Stock a Solid Choice Right Now? Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this make you sick? (Ad)The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments. Get your Free Wealth Protection Kit PRQR Media Mentions By Week PRQR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼-0.150.42▲Average Medical News Sentiment PRQR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼51▲PRQR Articles Average Week Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: scPharmaceuticals News Today Prelude Therapeutics News Today Capricor Therapeutics News Today Gossamer Bio News Today Rigel Pharmaceuticals News Today Repare Therapeutics News Today CervoMed News Today Alimera Sciences News Today CytomX Therapeutics News Today Skye Bioscience News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRQR) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”InvestorPlaceCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHow Biden has already won 2024Porter & CompanyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
